A comprehensive analysis of over 110,000 S. aureus genomes from 2000-2025 reveals that common aminoglycoside resistance genes are declining globally, while rare veterinary-linked variants are emerging in animal populations. Strong alignment between genetic markers and actual drug resistance suggests genomic surveillance could improve antibiotic stewardship.
Researchers conducted a meta-analysis of 110,309 S. aureus genomes collected across 128 countries over 25 years, applying computational tools to identify aminoglycoside resistance determinants and trace their distribution across human clinical, animal, environmental, and unknown sources. The study employed machine-learning models to predict drug susceptibility from genetic data, offering a quantitative view of how genomic architecture maps to phenotypic resistance.
The dominant resistance drivers were aminoglycoside-modifying enzymes (AMEs), with six major genes appearing in 14-22% of isolates worldwide: ant(6)-Ia, ant(9)-Ia, aph(3')-IIIa, sat4, aadD1, and aac(6')-Ie/aph(2'')-Ia. Temporal trends showed significant declines in several common determinants over the study period. Most notably, ant(9)-Ia decreased by 2.22 percentage points per year (p < 0.001), suggesting that clinical and public health pressure may be reducing the prevalence of these genes at the global scale. The study did not detect a statistically significant downward trend for apmA in animal isolates, though the direction of change was negative.
Host-specific patterns emerged clearly: human clinical isolates concentrated the common, well-characterized resistance genes, whereas animal and environmental isolates harbored rare alleles (apmA, spw, str, spd) that diverged from typical clinical profiles. Geographic mapping confirmed near-universal distribution of common genes across all regions, but focal or restricted presence of rare variants, suggesting that common determinants have established themselves globally while uncommon ones remain geographically clustered or niche-specific.
The genotype-phenotype concordance was strong, particularly for gentamicin and amikacin. Isolates carrying multiple aminoglycoside resistance genes predicted resistant minimum inhibitory concentration (MIC) strata, while absence of these determinants predicted susceptibility. Amikacin showed broad activity across the dataset, whereas gentamicin resistance concentrated in a distinct subpopulation whose genetic profile closely aligned with AME carriage. Critically, aminoglycoside resistance genes frequently co-occurred with determinants conferring resistance to other drug classes, including mecA (methicillin resistance), blaZ (beta-lactamase), and MLS_B (macrolide-lincosamide-streptogramin resistance). This pattern indicates that aminoglycoside resistance is embedded within multidrug-resistant genomic contexts on shared mobile genetic elements, complicating resistance management.
This study does not directly address health outcomes for individuals, but it provides important context for antibiotic stewardship and surveillance strategy. The findings suggest three practical implications:
1. Genomic surveillance is predictive. Strong concordance between resistance gene profiles and drug susceptibility indicates that whole-genome sequencing of clinical S. aureus isolates could accelerate identification of gentamicin and amikacin resistance, potentially faster than conventional susceptibility testing. However, phenotypic confirmation remains essential, particularly for borderline cases.
2. Aminoglycosides remain clinically viable. The global decline in common resistance determinants and the broad activity of amikacin suggest that aminoglycosides have not yet been rendered obsolete by resistance. This supports their continued judicious use in clinical settings, particularly for serious S. aureus infections when other options are limited.
3. Multidrug-resistant context matters. Because aminoglycoside resistance genes cluster with other resistance determinants on mobile elements, treatment decisions must account for the full resistance profile, not isolated resistance genes. Single-drug therapy is less likely to be effective in MDR contexts.
| Attribute | Detail |
|---|---|
| Study Type | Retrospective meta-analysis |
| Sample Size | 110,309 S. aureus genomes |
| Time Period | 2000-2025 |
| Geographic Coverage | 128 countries |
| Primary Data Source | Public genomic databases (NCBI) |
| Resistance Detection Method | AMRFinderPlus v4.0.23 |
| Stratification | Host source (human, animal, environmental, unknown); multilocus sequence typing; geographic region |
| Phenotypic Validation | Publicly available MIC data; strong genotype-phenotype correlation for gentamicin and amikacin |
| Statistical Methods | Robust regression for temporal trends; chi-square and enrichment tests for geographic/host structuring; elastic-net, random forests, and XGBoost for MIC prediction |
| Key Finding | Decline in common resistance genes globally; rare veterinary-linked alleles emerging in animal isolates; strong genotype-phenotype concordance; frequent co-occurrence with other resistance determinants |
| Journal | BMC Microbiology |
| PubMed ID |
Shen, Z., et al. "Comprehensive in silico genomics analysis of global trends and host-specific emergence of aminoglycoside resistance in Staphylococcus aureus: a One-Health perspective." BMC Microbiology, 2025. PubMed: 42661162
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.